A Prescription For Healthcare Investing

Funding new drug development is challenging. Trials are expensive, complex, and lengthy, and only a fraction of the therapeutics that go into clinical trials will ever come out the other side approved. Sarah Shores welcomes Dr. Andrew Lo, economist, professor at MIT and co-founder of QLS Advisors, a Quantitative Life Sciences Company working to accelerate the pace of change in biomedicine.